Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins.

R J Kreitman1

  • 1Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, 37/4B27, 37 Convent Drive Msc 4255 Bethesda, MD 20892, USA. kreitmar@mail.nih.gov

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Oncogene·2017
Same author

12 making fusion toxins to target leukemia and lymphoma.

Methods in molecular medicine·2011
Same author

Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.

Leukemia·2006
Same author

SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

Cancer gene therapy·2006
Same author

IBC's international Conference on Novel Therapeutic Proteins for Oncology (drug discovery and development).

Expert opinion on investigational drugs·2005
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Immunotoxins, including growth factor fusion toxins and recombinant immunotoxins, are novel targeted therapies designed to selectively kill diseased cells. While some are in development, one fusion toxin is approved, and others show promise in clinical trials for hematological malignancies.

Area of Science:

  • Biotechnology
  • Oncology
  • Immunology

Background:

  • Immunotoxins combine antibodies with protein toxins for targeted cell killing.
  • Conventional immunotoxins are in preclinical and clinical development but lack approval.
  • Growth factor fusion toxins and recombinant immunotoxins represent newer, efficiently produced classes.

Purpose of the Study:

  • To review the development and potential of immunotoxins as targeted therapies.
  • To differentiate between conventional immunotoxins, growth factor fusion toxins, and recombinant immunotoxins.
  • To highlight the clinical progress and future prospects of these targeted agents.

Main Methods:

  • Review of immunotoxin classes: conventional, growth factor fusion, and recombinant.
  • Discussion of molecular composition, production, and targeting mechanisms.

Related Experiment Videos

  • Analysis of clinical development status and reported responses, particularly in hematological malignancies.

    • Main Results:

    • One growth factor fusion toxin (IL-2/DT) is approved (Ontak); others are in development.
    • Recombinant immunotoxins offer efficient production and defined structures.
    • Clinical trials show significant responses with recombinant immunotoxins, especially in blood cancers.

    Conclusions:

    • Immunotoxins, particularly recombinant types, represent a distinct and promising targeted therapy modality.
    • Further clinical testing may lead to future approvals for treating various diseases, including cancers.
    • These agents offer a targeted approach separate from traditional chemotherapy, surgery, and radiation.